Condition: Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome · Sponsor: Ionis Pharmaceuticals, Inc.
The primary purpose of this study is to evaluate the safety and tolerability of ION440.
This description comes directly from the study's public registry record.
Ionis Pharmaceuticals · (844) 779-1497 · IonisMECP2study@clinicaltrialmedia.com
Always discuss trial participation with your own doctor first.
| Rady Children's Hospital | San Diego, California, United States | Recruiting |
| University of Colorado Hopsital - Anschutz Medical Campus | Aurora, Colorado, United States | Recruiting |
| Kennedy Krieger | Baltimore, Maryland, United States | Recruiting |
| Boston Children's Hospital | Boston, Massachusetts, United States | Recruiting |
| Gillette Children's Specialty Healthcare | Saint Paul, Minnesota, United States | Recruiting |
| Children's Hospital of Philadelphia | Philadelphia, Pennsylvania, United States | Recruiting |
| Vanderbilt University Medical Center | Nashville, Tennessee, United States | Recruiting |
| Baylor College of Medicine | Houston, Texas, United States | Recruiting |
| Kepler University Hospital | Linz, Austria | Recruiting |
| CHU Dijon Bourgogne | Dijon, France | Recruiting |
| Hospital Saint Joan de Deu | Barcelona, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06430385